Trial
NCT04525352
A Trial to Evaluate Safety and Efficacy of RP-L401-0120 in Subjects With Infantile Malignant Osteopetrosis
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Rocket Pharmaceuticals Inc.
Collaborators
California Institute for Regenerative Medicine (CIRM)
Condition
Infantile Malignant Osteopetrosis
Intervention
RP-L401
Why stopped
Study discontinued due to feasibility.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-07-13